The small molecule axl inhibitor BGB324 shows activity against T315I-mutated and BCR-ABL1 wt chronic myeloid leukemia

被引：0

作者：

Erdmann, R. ^{[1
,2
]}

Jorgensen, H. ^{[3
]}

Ben-Batalla, I. ^{[1
,2
]}

Kruse, N. ^{[1
,2
]}

Micklem, D. ^{[4
]}

von Amsberg, G. ^{[1
]}

Schafhausen, P. ^{[1
]}

Schultze, A. ^{[1
]}

Wroblewski, M. ^{[1
,2
]}

Binder, M. ^{[1
]}

Cubas-Cordova, M. ^{[1
,2
]}

Hadlich, T. ^{[1
]}

Janing, M. ^{[1
,2
]}

Sawall, S. ^{[1
,2
]}

Witzke, V. ^{[1
,2
]}

Lorens, J. ^{[4
]}

Allan, E. ^{[3
]}

Mukherjee, L. ^{[3
]}

Morrison, H. ^{[3
]}

Cassells, J. ^{[3
]}

Koerger, N. ^{[5
]}

Lorens, J. B. ^{[6
]}

Clark, R. ^{[7
]}

Koschmieder, S. ^{[8
]}

Vandenberghe, P. ^{[9
]}

Bruemmendorf, T. ^{[8
]}

Hochhaus, A. ^{[10
]}

Carmeliet, P. ^{[11
]}

Holyoake, T. ^{[3
]}

Pantel, K. ^{[2
]}

Bokemeyer, C. ^{[1
,12
]}

Loges, S. ^{[1
,2
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Med Clin 2, Hamburg, Germany

[2] Dept Tumor Biol, Hamburg, Germany

[3] Univ Glasgow, Paul OGorman Leukemia Res Ctr, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland

[4] BerGenBio AS, Jonas Lies, Bergen, Norway

[5] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Bone Marrow Transplantat Unit, Hamburg, Germany

[6] Univ Bergen, Dept Biomed, Bergen, Norway

[7] Univ Liverpool, Royal Liverpool Univ Hosp, Liverpool L69 3BX, Merseyside, England

[8] Univ Klinikum RWTH Aachen, Aachen, Germany

[9] Katholieke Univ Leuven, Ctr Human Genet, Leuven, Belgium

[10] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany

[11] VIB, Lab Angiogenesis & Neurovasc Link, Vesalius Res Ctr, Leuven, Belgium

[12] Univ Med Ctr Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Hematol & Oncol, Hamburg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V935

引用

页码：309 / 309

页数：1

共 50 条

[41] The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy
Malcikova, Jitka
Razga, Filip
Jurcek, Tomas
Dvorakova, Dana
Zackova, Daniela
Toskova, Martina
Sebejova, Ludmila
Smardova, Jana
Oltova, Alexandra
Vankova, Gabriela
Jurackova, Lenka
Trbusek, Martin
Pospisilova, Sarka
Mayer, Jiri
Racil, Zdenek
LEUKEMIA & LYMPHOMA, 2013, 54 (09) : 2083 - 2087
[42] The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia
Lange, Thoralf
Ernst, Thomas
Gruber, Franz X.
Maier, Jacqueline
Cross, Michael
Mueller, Martin C.
Niederwieser, Dietger
Hochhaus, Andreas
Pfirrmann, Markus
HAEMATOLOGICA, 2013, 98 (05) : 714 - 717
[43] SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia
Wang, Duowei
Zheng, Yan
Li, Jiaying
Wu, Hongxi
Li, Xianjing
Tang, Ying
Liu, Yang
Li, Jiani
Sun, Rui
Zhou, Youli
Sun, Jihong
Yang, Yong
EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 811 : 117 - 124
[44] Critical role of protein kinase CK2 in chronic myeloid leukemia cells harboring the T315I BCR::ABL1 mutation
Meza, Camila Paz Quezada
Salizzato, Valentina
Calistri, Elisabetta
Basso, Marco
Zavatti, Manuela
Marmiroli, Sandra
Salvi, Mauro
Carter, Bing Z.
Donella-Deana, Arianna
Borgo, Christian
Ruzzene, Maria
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 286
[45] 10058-F4 A SMALL MOLECULE C-MYC INHIBITOR DECREASES CIP2A AND REDUCES BCR-ABL1 TYROSINE KINASE ACTIVITY IN CHRONIC MYELOID LEUKAEMIA (CML)
Lucas, C.
Harrisl, R.
Giannoudis, A.
Clark, R.
HAEMATOLOGICA, 2013, 98 : 55 - 55
[46] AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
O'Hare, Thomas
Shakespeare, William C.
Zhu, Xiaotian
Eide, Christopher A.
Rivera, Victor M.
Wang, Frank
Adrian, Lauren T.
Zhou, Tianjun
Huang, Wei-Sheng
Xu, Qihong
Metcalf, Chester A., III
Tyner, Jeffrey W.
Loriaux, Marc M.
Corbin, Amie S.
Wardwell, Scott
Ning, Yaoyu
Keats, Jeffrey A.
Wang, Yihan
Sundaramoorthi, Raji
Thomas, Mathew
Zhou, Dong
Snodgrass, Joseph
Commodore, Lois
Sawyer, Tomi K.
Dalgarno, David C.
Deininger, Michael W. N.
Druker, Brian J.
Clackson, Tim
CANCER CELL, 2009, 16 (05) : 401 - 412
[47] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Qian Jiang
Zongru Li
Yazhen Qin
Weiming Li
Na Xu
Bingcheng Liu
Yanli Zhang
Li Meng
Huanling Zhu
Xin Du
Suning Chen
Yang Liang
Yu Hu
Xiaoli Liu
Yongping Song
Lichuang Men
Zi Chen
Qian Niu
Hengbang Wang
Ming Lu
Dajun Yang
Yifan Zhai
Xiaojun Huang
Journal of Hematology & Oncology, 15
[48] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Jiang, Qian
Li, Zongru
Qin, Yazhen
Li, Weiming
Xu, Na
Liu, Bingcheng
Zhang, Yanli
Meng, Li
Zhu, Huanling
Du, Xin
Chen, Suning
Liang, Yang
Hu, Yu
Liu, Xiaoli
Song, Yongping
Men, Lichuang
Chen, Zi
Niu, Qian
Wang, Hengbang
Lu, Ming
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
[49] Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis
Huang, Wei-Ching
Tsai, Cheng-Chieh
Chen, Chia-Ling
Chen, Tsai-Yun
Chen, Ya-Ping
Lin, Yee-Shin
Lu, Pei-Jung
Lin, Chun-Mao
Wang, Shwu-Huey
Tsao, Chiung-Wen
Wang, Chi-Yun
Cheng, Yi-Lin
Hsieh, Chia-Yuan
Tseng, Po-Chun
Lin, Chiou-Feng
FASEB JOURNAL, 2011, 25 (10): : 3661 - 3673
[50] Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Qian Jiang
Zongru Li
Yazhen Qin
Weiming Li
Na Xu
Bingcheng Liu
Yanli Zhang
Li Meng
Huanling Zhu
Xin Du
Suning Chen
Yang Liang
Yu Hu
Xiaoli Liu
Yongping Song
Lichuang Men
Zi Chen
Qian Niu
Hengbang Wang
Ming Lu
Dajun Yang
Yifan Zhai
Xiaojun Huang
Journal of Hematology & Oncology, 16

← 1 2 3 4 5 →